A novel strategy for remission induction and maintenance in cancer therapy

Tsuda, Hitoshi; Sata, Masafumi; Ijuuin, H.; Kumabe, Tutomu; Uchida, Masafumi; Ogou, Yoshio; Akagi, Yusuke; Shirouzu, Kazuo; Hara, Hisashi; Nakashima, Yutaka

doi:10.3892/or.9.1.65

Cited by 7 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So inhibition of survivin expression with intention to induce apoptosis in cancer cells might prove to be a useful new method for cancer therapy. [36][37][38] Transient and persistent disruption of survivin gene expression in several types of cancer cells was achieved previously by genetic deletion, anti-sense oligonucleotides, dominant negative inhibitors and siRNAs, 23,[39][40][41] and has been shown to enhance PCD. 42 In this study, we show that suppressing survivin expression or function causes cell cycle arrest at the G 1 phase and spontaneous apoptosis in breast cancer SKBr-3 cells.…”

Section: Discussionmentioning

confidence: 99%

Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers

Li¹,

Zhao²,

Liu³

et al. 2006

Cancer Biology & Therapy

View full text Add to dashboard Cite

Increased resistance to apoptosis is a hallmark of many tumor cells. Survivin, a member of IAP family protein, is expressed in many human cancers and plays an important role in protecting cells from apoptosis. Here we show that vector-based small interfering RNAs (siRNA) stably knockdown survivin expression in several cancer cell lines, leading to increased apoptotic rate in response to different proapoptotic stimuli, such as doxorubicin or TNF-α. The apoptotic susceptibility was dependent on divergent levels of survivin expression. The stable transfectants exhibited abnormal morphology, suppressed cell growth, enhanced spontaneous apoptosis and cell cycle hindrance. Furthermore, in nude mice xenografts of survivin-positive tumors, cells expressing survivin-targeted siRNAs exhibited decreased tumor formation and reduced angiogenesis. Results from these studies:(1) provide direct evidence that intracellular silencing of survivin by siRNA sensitizes human tumor cells to apoptosis; (2) define survivin as a promising molecular target for cancer therapy; and (3) suggest the potential applicability of survivin-targeted siRNA for treating human tumors, probably in combination with chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers

Li¹,

Zhao²,

Liu³

et al. 2006

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…This study documented the reduction of oval cells formation by ChV supplementation in the liver cancer-induced rats. ChV contains a variety of antioxidants such as ascorbic acid, tocopherols and reduced glutathione [ 71 ], and has the potential as an anticancer agent which can restrict and suppress the growth of initiated clonal cell populations into foci or preneoplastic nodules and HCC [ 72 , 73 , 74 ].…”

Section: Discussionmentioning

confidence: 99%

Elevation of tumour markers TGF-β, M2-PK, OV-6 and AFP in hepatocellular carcinoma (HCC)-induced rats and their suppression by microalgae Chlorella vulgaris

et al. 2017

View full text Add to dashboard Cite

Background Chlorella vulgaris (ChV), a unicellular green algae has been reported to have anticancer and antioxidant effects. The aim of this study was to determine the chemopreventive effect of ChV on liver cancer induced rats by determining the level and expression of several liver tumour markers.MethodsMale Wistar rats (200–250 g) were divided into 4 groups according to the diet given: control group (normal diet), ChV group with three different doses (50, 150 and 300 mg/kg body weight), liver cancer- induced group (choline deficient diet + 0.1% ethionine in drinking water or CDE group), and the treatment group (CDE group treated with three different doses of ChV). Rats were killed at 0, 4, 8 and 12 weeks of experiment and blood and tissue samples were taken from all groups for the determination of tumour markers expression alpha-fetoprotein (AFP), transforming growth factor-β (TGF-β), M2-pyruvate kinase (M2-PK) and specific antigen for oval cells (OV-6).ResultsSerum level of TGF-β increased significantly (p < 0.05) in CDE rats. However, ChV at all doses managed to decrease (p < 0.05) its levels to control values. Expressions of liver tumour markers AFP, TGF-β, M2-PK and OV-6 were significantly higher (p < 0.05) in tissues of CDE rats when compared to control showing an increased number of cancer cells during hepatocarcinogenesis. ChV at all doses reduced their expressions significantly (p < 0.05).Conclusions Chlorella vulgaris has chemopreventive effect by downregulating the expression of tumour markers M2-PK, OV-6, AFP and TGF-β, in HCC-induced rats.

show abstract

“…The emerging understanding of the multitude of genetic aberrations in cancer has driven the field of cancer gene therapy to focus on rescuing defective genetic lesions by delivering the wild type product by gene transfer [13]. The P53 gene is a commonly mutated gene in tumors and the mutations are linked to the occurrence and development of cancer [14,15].…”

Section: Discussionmentioning

confidence: 99%

Antitumor Activity of a Combination of rAd2p53 Adenoviral Gene Therapy and Radiotherapy in Esophageal Carcinoma

Yang

Huang

et al. 2011

Cell Biochem Biophys

View full text Add to dashboard Cite

The objective of this study was to determine if a combination of recombinant adenovirus 2 p53 (rAd2p53) gene therapy and radiotherapy would have significantly improved outcome from esophageal carcinoma when compared to radiotherapy (RT) alone. Forty-five patients diagnosed with esophageal carcinoma (confirmed squamous cell carcinoma) were randomly assigned to one of two study arms: treatment group: rAd2p53 gene therapy + RT (n = 22); and control group: radiotherapy (n = 23). For the treatment group, rAd2p53 was injected into multiple areas of the lesion once a week for 6 weeks avoiding deep ulcers points. RT was administered after 3 days of injection of rAd2p53. Patients in the control group only received radiotherapy. The overall response rate was significantly higher in the treatment group than in control group (P < 0.05). Furthermore, the complete response rate was 3 times higher in the treatment group than in the control group (P < 0.05). Transient fever and pain at injection site were the only side effects mentioned in the treatment group. In conclusion, this recombinant virus-RT combination is significantly more beneficial in palliation than RT alone, with minor side affects. However, its role as neoadjuvant therapy prior to surgical resection needs to be further investigated.

show abstract

A novel strategy for remission induction and maintenance in cancer therapy

Cited by 7 publications

References 0 publications

Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers

Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers

Elevation of tumour markers TGF-β, M2-PK, OV-6 and AFP in hepatocellular carcinoma (HCC)-induced rats and their suppression by microalgae Chlorella vulgaris

Antitumor Activity of a Combination of rAd2p53 Adenoviral Gene Therapy and Radiotherapy in Esophageal Carcinoma

Contact Info

Product

Resources

About